Search hospitals > Colorado > Denver
Rocky Mountain Cancer Centers-Midtown
Claim this profileDenver, Colorado 80218
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Colorectal Cancer
Conducts research for Pancreatic Cancer
388 reported clinical trials
10 medical researchers
Summary
Rocky Mountain Cancer Centers-Midtown is a medical facility located in Denver, Colorado. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer and other specialties. Rocky Mountain Cancer Centers-Midtown is involved with conducting 388 clinical trials across 468 conditions. There are 10 research doctors associated with this hospital, such as Nicholas DiBella, Allen L. Cohn, Manojkumar Bupathi, MD, MS, and John M. Burke, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder6 years of reported clinical research
Expert in Breast Cancer
Expert in Lung Cancer
103 reported clinical trials
193 drugs studied
Allen L. CohnRocky Mountain Cancer Centers3 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
36 drugs studied
Manojkumar Bupathi, MD, MSRocky Mountain Cancer Center1 year of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
10 reported clinical trials
22 drugs studied
John M. Burke, MDRocky Mountain Cancer Centers - Aurora13 years of reported clinical research
Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
7 reported clinical trials
13 drugs studied
Clinical Trials running at Rocky Mountain Cancer Centers-Midtown
Lung Cancer
Breast Cancer
Colorectal Cancer
Cancer
Prostate Cancer
Breast cancer
Pancreatic Cancer
Melanoma
Bladder Cancer
Ovarian Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Rocky Mountain Cancer Centers-Midtown?
Rocky Mountain Cancer Centers-Midtown is a medical facility located in Denver, Colorado. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Colorectal Cancer, Pancreatic Cancer and other specialties. Rocky Mountain Cancer Centers-Midtown is involved with conducting 388 clinical trials across 468 conditions. There are 10 research doctors associated with this hospital, such as Nicholas DiBella, Allen L. Cohn, Manojkumar Bupathi, MD, MS, and John M. Burke, MD.
Where is Rocky Mountain Cancer Centers-Midtown located?
The Rocky Mountain Cancer Centers-Midtown is situated at 1800 N. Williams St., Ste. 200, Denver, CO 80218. It is conveniently located near HealthOne Presbyterian St. Luke’s Medical Center and Exempla St. Joseph Hospital. For access, head east on N. Williams St. from downtown Denver and turn right into the parking lot before reaching 18th Ave.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Rocky Mountain Cancer Centers-Midtown, call (303) 388-4876. Financial counselors are on hand to assist with understanding treatment costs and establishing a financial plan. Update insurance information via their electronic form or directly contact your clinic to confirm network status with your provider.
What insurance does Rocky Mountain Cancer Centers-Midtown accept?
Rocky Mountain Cancer Centers-Midtown accepts a variety of insurance plans, including but not limited to Aetna, Anthem BCBS Colorado, Apostrophe Health, Cigna, Colorado Access, First Health, and Humana Medicare Advantage. They strive to provide access to their facilities for as many individuals as possible and are in-network for most insurance plans. It is crucial to contact both your insurance provider and the clinic to confirm network status and understand your specific coverage.
What awards or recognition has Rocky Mountain Cancer Centers-Midtown received?
Rocky Mountain Cancer Centers-Midtown, located in Denver, Colorado, is renowned for its personalized, world-class cancer care, with a remarkable 90% of patients recommending it. The center has contributed to over 100 FDA-approved cancer therapies. It provides a comprehensive range of treatments and services, including clinical research trials.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.